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Abstract
Background: The Home Management of Malaria (HMM) strategy was developed using chloroquine, a now obsolete drug, which
has been replaced by artemisinin-based combination therapy (ACT) in health facility settings. Incorporation of ACT in HMM
would greatly expand access to effective antimalarial therapy by the populations living in underserved areas in malaria endemic
countries. The feasibility and acceptability of incorporating ACT in HMM needs to be evaluated.
Methods: A multi-country study was performed in four district-size sites in Ghana (two sites), Nigeria and Uganda, with
populations ranging between 38,000 and 60,000. Community medicine distributors (CMDs) were trained in each village to
dispense pre-packaged ACT to febrile children aged 6–59 months, after exclusion of danger signs. A community mobilization
campaign accompanied the programme. Artesunate-amodiaquine (AA) was used in Ghana and artemether-lumefantrine (AL) in
Nigeria and Uganda. Harmonized qualitative and quantitative data collection methods were used to evaluate CMD performance,
caregiver adherence and treatment coverage of febrile children with ACTs obtained from CMDs.
Results: Some 20,000 fever episodes in young children were treated with ACT by CMDs across the four study sites. Cross-
sectional surveys identified 2,190 children with fever in the two preceding weeks, of whom 1,289 (59%) were reported to have
received ACT from a CMD. Coverage varied from 52% in Nigeria to 75% in Ho District, Ghana. Coverage rates did not appear
to vary greatly with the age of the child or with the educational level of the caregiver. A very high proportion of children were
reported to have received the first dose on the day of onset or the next day in all four sites (range 86–97%, average 90%). The
proportion of children correctly treated in terms of dose and duration was also high (range 74–97%, average 85%). Overall, the
proportion of febrile children who received prompt treatment and the correct dose for the assigned duration of treatment
ranged from 71% to 87% (average 77%). Almost all caregivers perceived ACT to be effective, and no severe adverse events were
reported.
Conclusion: ACTs can be successfully integrated into the HMM strategy.
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Background
Home Management of Malaria (HMM) for children with
uncomplicated malaria in high transmission areas in
Africa is an integral part of malaria case management
within the overall Roll Back Malaria (RBM) strategy [1]. If
the Abuja target of 60% of uncomplicated malaria epi-
sodes receiving effective treatment within 24 hours [2]
and the Millennium Development Targets 5, 8 and 17
(reducing childhood mortality, halting the increase in
malaria incidence and providing access to affordable
essential drugs in developing countries) [3] are to be met,
there is an urgent need to increase access to effective
malaria treatment at the community level, especially in
underserved rural areas.
So far, 18 African countries have adopted HMM as part of
their malaria control programme [4]. Due to unacceptable
levels of resistance to chloroquine by Plasmodium falci-
parum, 44 countries in Africa have adopted artemisinin-
based combination therapy (ACT) as the first line treat-
ment for uncomplicated malaria [5]. However, in most
cases, the deployment of ACT is currently limited to
health facilities, with large scale implementation of HMM
using ACT delayed by concerns about the use of ACT at the
community level [6-8].
A major concern with using ACT at the community level
is the potential for poor adherence to the treatment sched-
ule by both caregivers and community medicine distribu-
tors (CMDs). This could facilitate the development of
parasite resistance to these expensive but currently highly
efficacious drugs. Other concerns relate to acceptability by
the community, the incidence of adverse events, cost and
ability to provide adequate storage conditions to ensure
drug stability in the community.
A pilot study carried out in Ghana in 2004 [9] provided
preliminary evidence for the feasibility and acceptability
of the use of artemether-lumefantrine (AL) in the HMM
context. However, this study was essentially a qualitative
assessment of community acceptability. To provide addi-
tional evidence to support the use of ACT at the commu-
nity level, the UNICEF-UNDP-WORLD BANK-WHO
Special Programme for Research and Training in Tropical
Diseases (TDR) funded four studies in sites in Ghana,
Nigeria and Uganda, representing different health system
and epidemiological settings. This paper reports on the
feasibility, acceptability and utilization of ACT provided
at the community level.
Methods
Study sites and population
This multi-country study was performed in Ghana (two
sites), Nigeria and Uganda all in sub-Saharan Africa. In
Ghana two districts, Ejisu-Juaben and Ho were studied
and in Ho district, an urban and a rural site were studied.
In Nigeria, two districts Badeku and Ojoku/Ajia in Ona-
ara local government were studied. The sites in Ejisu-Jua-
ben, Ghana; Ona-ara Local Government, Nigeria; and
Buguri and Iganga districts, Uganda were all rural areas.
Ghana and Nigeria are located in West Africa, while
Uganda is in East Africa. Table 1 describes the location
and population characteristics of the different study sites,
details of the community-based medicine distributors
(CMDs) deployed, their training and supervision proc-
esses, and type, dosing schedule and cost to the end user
of the antimalarial drug used.
Study design
The study was conducted in three phases. The first phase
involved advocacy, community mobilization, selection of
CMDs and establishment of key baseline indicators. Infor-
mation, Education and Communication (IEC) materials
were developed and research staff recruited and trained.
The intervention phase involved the training of CMDs
and distribution of ACT. A year after commencement of
ACT distribution, a household survey, interviewing eligi-
ble caregivers about child fevers in the past two weeks, was
performed to evaluate the intervention.
Sample size
It was decided that to yield useful results in terms of feasi-
bility, the study should cover populations with a mini-
mum population of around 40,000 – the size of a typical
district. The sample size for the household survey was cal-
culated using country-specific fever prevalence rates to
provide a precision of ± 5% for the estimates of coverage
of ACT treatment through CMDs, assuming a design effect
of two. The minimum number of households to be inter-
viewed ranged from 700 to 768.
Data collection methods
Qualitative and quantitative data collection methods were
used. Data collection tools for all the sites were harmo-
nized prior to the intervention with some country specific
modifications. The tools included the survey question-
naire and focus group discussion (FGD) and key inform-
ant interview (KII) guides, which were pre-tested and
translated into the local languages. The format of CMDs'
registers was also harmonized. The household survey
focused on the health-seeking behaviour of caregivers of
children with fever in the preceding two weeks, with an
emphasis on timeliness of treatment, compliance with the
prescribed treatment course, and perceptions of effective-
ness and drug related adverse events. The FGD and KII
guides focused on health-seeking behaviours, beliefs
about the aetiology of malaria, treatment practices and
community perceptions of the intervention.
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Community medicine distributors
Community medicine distributors were trusted members
of the community who were chosen by the community
from a range of backgrounds, including farmers, chemi-
cal/medicine sellers, teachers, traders, community health
workers, artisans, 'mother trainers', and opinion leaders
(Table 1). In Ghana and Nigeria nurses and community
health officers at first-level formal health facilities were
counted as CMDs. 'Mother trainers' were lay mothers who
were selected from within the communities and trained to
distribute drugs.
Selection criteria for CMDs included being a permanent
resident (at least one year), trusted and respected by the
community, able to keep simple records, and a willing-
ness to serve. Uganda had a functioning pre-existing cadre
of CMDs who were co-opted into the study. The number
of CMDs per community depended on the community's
population size. An average of two CMDs per community
was used across the four sites (one CMD per 600 popula-
tion).
Although CMDs were not paid a salary, various motiva-
tion mechanisms were used. Some of these included rain
coats, bicycles, boots, watches, T-shirts and certificates of
participation. Quarterly monetary allowances varied
between USD 4.5 (Uganda), USD 5 (Ejisu-Juaben) and
USD 8 (Ho). In Nigeria, the CMDs received a commission
of between USD 0.20 and USD 0.30 for each pack of AL
dispensed in addition to periodic gifts and reimburse-
ment of transportation fares.
Drugs used in the study
Two different ACTs were used in accordance with the
national drug policies of the participating countries; AL
was used in Uganda and Nigeria, and artesunate-amodi-
aquine (AS/AQ) was used in Ghana.
For the AS/AQ combination, blister packs containing co-
packed artesunate and amodiaquine tablets of 50 and 153
mgs respectively were used. For children aged 12 to 59
months the recommended dose of AS/AQ was one tablet
of each drug once per day. However, for children of six to
11 months of age, tablets had to be broken in half and
repackaged to comply with the recommended AS/AQ
dose in that age group.
In Nigeria and Uganda, a fixed combination of 20 mg of
artemether and 120 mg of lumefantrine (AL) in two types
of blister pack, one for children below three years of age
Table 1: Description of study sites and intervention implementation in four sites evaluating home management of malaria with 
artemisinin combination therapy
Ejisu – Juaben District, Ghana Ho District, Ghana Badeku and Ojoku/Ajia 
Districts, Nigeria
Bugiri and Iganga Districts, 
Uganda
Population 
characteristics
35 rural communities
Population c. 38,000
Perennial malaria 
transmission
49 urban & rural communities
Population c. 42,000
Perennial malaria 
transmission
40 rural communities
Population 43,000
Perennial, hyperendemic 
malaria transmission
56 rural communities
Population c. 60,000
Perennial, hyperendemic 
transmission
Community medicine 
distributors
54 (51 male) trusted 
members of community 
(farmers, teachers, drug 
sellers), chosen by the 
community
76 (48 male) trusted 
members of community 
(farmers, teachers, drug 
sellers), chosen by the 
community
60 (4 male) including drug 
sellers, health workers and 
mothers chosen by the 
communities
118 (62 male) pre-existing 
cadre of CMDs (chosen by 
the community)
5 days of training 2 days of training 2 days of training 2 days of training
Provided with bicycles, boots 
& $3.50 monthly
Provided with T-shirts, 
watches, raincoats, torches & 
US$8 quarterly
Received commission of 
20–30 US cents per pack 
distributed. Provided with T-
shirts, transport 
reimbursement, Festivity gift, 
and certificates.
Transport refund of USD 
1.16 per meeting. T-shirts, 
baseball caps, certificates
Bimonthly supervision by 
research staff; Monthly 
supervision by community 
Health Officers
Monthly supervision by health 
staff and quarterly meetings
Monthly supervision by 
research staff
Monthly supervision by health 
staff
CMDs were not obliged to follow up caregivers. However, 
some of them followed up and some gave drugs under direct 
observation.
No active follow-up of 
caregivers by CMDs.
Program ran within existing 
home management system. 
CMDs actively followed up 
treated children to establish 
treatment outcome
Drugs and dosing 
schedule
Artesunate+Amodiaquine (ASAQ) once daily for 3 days
2 types of blister pack, for children < 1 year and children 1 
year and above
Artemether-lumefantrine (Coartem®) twice daily for 3 days
2 types of blister pack, for children < 3 years and children 3 
years and above
10 US cents for <1 year
20 US cents for 1 year and above
20 US cents for < 3 years
30 US cents for 3 years and 
above Charged for first 6 
months only, thereafter free
Free
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and another for children three years and above, were used.
The recommended dose for children aged six to 35
months was one tablet twice daily for three days, and for
children aged 36 to 59 months two tablets twice daily for
three days. Caregivers were advised to administer the drug
after meals, preferably fatty food.
Drug supply
In all the sites, drugs were provided through existing pub-
lic health structures, at health district or sub-district level.
In general, the distribution points for drugs were the local
health facilities. In Uganda, CMDs replenished their stock
at monthly meetings at health facility level. In Nigeria and
Ghana, CMDs replenished their stocks from the health
facilities as the need arose. In some instances drugs were
delivered by the research team or by health staff during
supervisory visits.
Supervision
Monthly supervision was undertaken in all sites, by health
staff or by the research team (Table 1). In each site, super-
vision included checking drug stocks, their storage condi-
tions, and the CMDs' registers. The research team
provided fuel and travel allowances to supervisors. In
Nigeria, unscheduled inspections were periodically
undertaken.
Data analysis
EPI info version 6.02, SPSS version 11.0 and STATA ver-
sion 9.2 were used by the four sites to enter and analyse
data. A set of indicators and quantitative analyses to be
performed were agreed in discussion with research staff
from each site. Each research team then undertook the
analysis of their own data using standard statistical meth-
ods. The FGD and KII information was transcribed and
content analysis performed. From the transcripts and field
notes, the responses to questions asked to explore issues
of interest were grouped together, coded, categorized and
analysed according to emerging themes. The findings were
interpreted and reported in the form of narratives.
Ethics
Ethical approval for conduct of this study was obtained
from the WHO Ethics Review Committee and at national
level from the appropriate Ethical Review Boards.
Informed consent was obtained from community heads,
household heads and the caregivers who participated in
the study.
Results
Utilization of CMDs
Based on the records maintained by the CMDs, some
20,000 fever episodes in young children were treated with
ACTs by CMDs across the four study sites (Table 2). The
total number of episodes treated varied considerably
between sites as did the average number of episodes
treated per CMD (from 17 per CMD in Nigeria to 93 in
Uganda). The higher number of episodes treated in
Uganda may be explained by the fact that home-based
management of fevers has been implemented there since
2001. A higher attrition rate of CMDs in Nigeria com-
pared to other study sites may also have contributed to the
lower figures recorded there. Slightly more girls (4,928)
than boys (4,595) were treated across the three sites in
which this information was recorded. In this study, the
accurate population denominators were not available.
However, taking into account the width of the age groups,
utilization appeared to decline somewhat with age (from
3,571 children in the 6-month age band from 6–11
months to 6,627 children in the two year age band from
36–59 months). Utilization was generally prompt with at
least half of all children presenting on the day of onset or
Table 2: Utilization of CMDs for treatment of children with fever in 4 sites (source: CMD registers)
Ejisu – Juaben 
District, Ghana
Ho District, 
Ghana
Badeku and Ojoku/Ajia 
Districts, Nigeria
Bugiri and Iganga 
Districts, Uganda
Totals
Number of CMDs 54 76 60 118 308
Total number febrile episodes in children less 
than 5 treated with ACTs by CMDs
4522 3958 1044 11039 20563
Number (%) treated by age
6–11 months 789 (17%) 474 (12%) 99 (9%) 2209 (20%) 3571 (17%)
12–23 months 1531 (34%) 1157 (29%) 186 (18%) 2571 (23%) 5445 (26%)
24–35 months 1082 (24%) 1054 (27%) 236 (23%) 2548 (23%) 4920 (24%)
36–59 months 1120 (25%) 1273 (32%) 523 (50%) 3711 (34%) 6627 (32%)
Number (%) treated by sex
Female 2458 (54%) 1977 (50%) 493 (47%) NA 4928 (52%)
Male 2064 (46%) 1980 (50%) 551 (53%) NA 4595 (48%)
Number (%) treated by promptness of utilization
Same day 2636 (58%) 2125 (54%) 479 (49%) 5445 (49%) within 
24 hours
14124 (69%)
Next day 1886 (42%) 1313 (33%) 240 (24%)
Later than next day 0 (0%) 520 (13%) 263 (27%) 5594 (51%) 6377 (31%)
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within 24 hours of onset in all four sites. In the three sites
which recorded promptness as "same day" or "next day"
73–90% of children presented on the day of onset or the
next day.
Treatment coverage of febrile episodes by CMDs
Data from the community-based cross-sectional surveys
were used to estimate the proportion of febrile children
receiving ACT from CMDs. A total of 2,190 children with
fever in the two weeks preceding the survey were identi-
fied of whom 1,289 (59%) were reported to have received
ACT from a CMD (Table 3). Coverage varied from 52% in
Nigeria to 75% in Ho District, Ghana (P < 0.001). Cover-
age rates did not appear to vary greatly with age, except
perhaps in Ejisu-Juaben District, Ghana, where coverage
appeared lower in the six to 11 months age group than in
older age groups (Table 3). Overall, across the four sites,
treatment coverage did not appear to vary strongly with
the educational level of the caregiver.
CMD performance
Based on the information recorded by the CMDs in their
registers, a very high proportion of children received the
correct dose of ACTs (97% or greater in all sites; Table 4).
From the survey data, CMDs were reported to have
explained the dosing schedule on a very high proportion
of occasions (>90% in all sites), but performed less well
with respect to explaining danger signs or possible adverse
events (Table 4). This was particularly pronounced in
Ejisu-Juaben District in Ghana. Availability of CMDs was
reported to be good, with 85% or more of caretakers
reporting that they found the CMD at the first time of vis-
iting.
A young woman in Nigeria said:
'CMDs are always available. It is good we have two in our
community, when one is out the village the other one
attends to caregivers'.
In two of the four sites there was some turnover of CMDs
but the attrition rate in these sites was relatively low. The
need for incentives for CMDs, however, was often men-
tioned as an issue. An opinion leader in Ho, Ghana, said:
There is this saying that "the one who feeds a child will
surely put her hands in her mouth"; our volunteers should
be appreciated so that they can enjoy the work they are
doing. For this, the community and I will think about it and
compensate them by giving some allowance because some-
times they have to go and call them from wherever they are.
Caregiver adherence
From the survey data, a very high proportion of children
were reported to have been treated promptly in all four
sites (Table 5). The proportion of febrile children who
received prompt treatment and received the correct dose
for the assigned duration of treatment ranged from 71%
in Uganda to 87% in Ghana (P < 0.001; Table 5). Adher-
ence by caregivers was linked to better treatment outcome.
A woman participating in a FGD in Ejisu-Juaben district
said:
"When I went in for the drug he gave me instructions on
how to give the drug to the child. I was told to give it to him
continuously for three days – two tablets (white & yellow)
each day. I did that and afterwards the child was well
again. Happiness was then restored in my home".
Table 3: Treatment coverage of febrile children aged 6–59 months with ACTs obtained from CMDs (source: household survey)
Ejisu – Juaben 
District, Ghana
Ho District, 
Ghana
Badeku and Ojoku/Ajia 
Districts, Nigeria
Bugiri and Iganga 
Districts, Uganda
Totals
Total number of febrile children identified 428 124 551 1087 2190
Number (%) treated with ACTs from a CMD 289 (68%) 93 (75%) 288 (52%) 619 (57%) 1289 (59%)
95% CI 61–74% 63–87% 44–61% 51–63%
Number treated (% coverage) by age in months
6–11 20 (45%) 13 (76%) 17 (53%) 16 (52%) 66(53%)
12–23 89 (74%) 21 (81%) 49 (49%) 179 (56%) 338 (60%)
24–35 64 (73%) 25 (76%) 69 (52%) 142 (56%) 300 (59%)
36–59 116 (66%) 28 (72%) 153 (54%) 282 (58%) 579 (59%)
Number treated (% coverage) by sex
Female 137 (65%) 46 (72%) 154 (54%) NA 337 (60%)
Male 152 (70%) 47 (78%) 134 (50%) NA 333 (61%)
Number treated (%) coverage by educational level of caregiver
None 71 (75%) 20 (77%) 80 (47%) 192 (54%) 363 (56%)
Primary 74 (68%) 28 (80%) 155 (56%) 315 (56%) 572 (58%)
Secondary 144 (64%) 45 (76%) 53 (52%) 112 (65%) 354 (63%)
Number treated (% coverage) by marital status of caregiver
Married 219 (67%) 87 (75%) 256 (54%) 571 (56%) 914 (47%)
Not married 70 (69%) 6 (75%) 30 (41%) 48 (63%) 127 (49%)
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A local council chairperson of Bwalula village in Uganda
explained:
From 1–2 weeks during Homapak, it now takes about three
months before my child gets sick. It is better than CQ when
you complete the dose.
Safety and perceived effectiveness of ACTs
The proportion of children for whom an adverse event
was reported to the CMD was low (circa 1%) in both sites
in which this information was available (Table 6). At the
survey the proportion of children reported to have experi-
enced an adverse event following treatment with ACT was
somewhat higher (4–8%) but none of these adverse
events were reported to be serious. In all sites almost all
caretakers perceived ACT to be effective. In Ho, Ghana, a
community member argued that:
"The change is that, previously, when children fall sick, we
take some time to look for money and walk all the distance
to go to the hospital. Sometimes before we get there the
child's condition becomes worse. If you are lucky to get to
the hospital early, after treatment you walk the same dis-
tance back or referred to the big hospital. The unlucky ones
either die before they get to the clinic or die at the clinic; but
ever since the introduction of this program, we have seen a
change. For a year now, since the introduction of the new
drug, no child has died and we have not sent any of them
to the hospital".
A caregiver added:
"As for the drug, it works like magic!"
Discussion
There are two major findings from this study. First, it
showed, at a larger scale than previously [9], that making
ACT available at the community level through trained
CMDs results in a high degree of adherence by sensitized
caregivers. Second, that community-based strategy can
deliver high coverage of febrile episodes in children with
prompt and adequate treatment. Importantly, these find-
Table 5: Adherence of caregivers to treatment schedule
Ejisu – Juaben 
District, Ghana
Ho District, 
Ghana
Badeku and Ojoku/Ajia 
Districts, Nigeria
Bugiri and Iganga 
Districts, Uganda
Totals
Number of episodes treated with ACTs from a 
CMD
289 93 288 619 1289
Number (%) of children correctly treated (dose 
and duration)
281 (97%) 69 (74%) 256 (89%) 490 (79%) 1096 (85%)
Number (%) of children treated promptly 
(receiving first dose on the same or next day)
259 (90%) 89 (96%) 278 (97%) 531 (86%) 1157 (90%)
Number (%) of children treated promptly AND 
correctly
252 (87%) 69 (74%) 231 (80%) 438 (71%) 990 (77%)
Table 4: Measures of CMD performance in delivering ACTs in 4 sites (source: CMD registers + household survey)
Ejisu – Juaben 
District, Ghana
Ho District, 
Ghana
Badeku and Ojoku/Ajia 
Districts, Nigeria
Bugiri and Iganga 
Districts, Uganda
Totals
Correctness of prescription (from CMD register)
Number (%) of all children correctly dosed 4473 (99%) 3900 (98%) 1019 (98%) 10,671 (97%) 20063 (98%)
Number (%) of young children receiving an 
over dose
30 (0.7%) 15 (3.2%) 11 (2%) 27 (0.4%) 83 (0.7%)
Number (%) of older children receiving an 
under dose
8 (0.2%) 43 (1.2%) 12 (3%) 54 (1.5%) 117 (1%)
Number (%) of occasions on which CMD explained (from survey):
Treatment schedule 281 (97%) 93 (100%) 264 (92%) 569 (92%) 1207 (94%)
Danger signs 53 (18%) 83 (89%) 240 (83%) 462 (75%) 838 (65%)
Possible adverse events 44 (15%) 86 (93%) 241 (84%) N/A 371 (55%)
Availability of CMDs (from survey)
Number (%) of mothers who did not find 
the CMD at the first attempt
36 (12%) 5 (5%) 36 (12.5%) 86 (14%) 163 (12.5%)
Storage of ACTs (from supervision records)
Number (%) of supervisory visits at which 
drugs were stored appropriately
523 (99%) 720 (100%) 960 (100%) 420 (100%) 2623 (99.8%)
Attrition of CMDs
Number (%) of CMDs withdrawing from 
role
0 (0%) 3 (4%) 6 (10%) 0 (0%) 9 (3%)
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ings are consistent in four different sites in sub-Saharan
Africa, both in West and East Africa.
There was high utilization of CMDs. In an estimated pop-
ulation of children aged 6 to 59 months across the sites of
27,450, the CMDs treated 20,563 episodes of fever during
the year of implementation (0.75 episodes of fever per
child on average)). This contrasts with the figure of
0.12–0.34 episodes per year reported from African health
facilities in available literature [10]. Furthermore, the
majority of caregivers reported that CMDs were available
at the first time of asking, and very little attrition of CMDs
was reported. This demonstrates the potential of CMDs to
increase access to care in underserved rural areas in Africa,
where government health facilities are often under-uti-
lized [11,12]. While every effort was made to ensure the
implementation of the study as close as possible to real
life conditions, its short duration and the research setting
are likely to have contributed to the low attrition rate of
CMDs observed in this study. Indeed, the need to provide
CMDs with incentives was repeatedly mentioned in inter-
views and FGDs, and financial motivation is known to be
a key factor determining long term performance of CMDs
[13]. It is clear that this need must be addressed to ensure
the long-term sustainability of CMDs performance.
Concerns have been raised by several authors about the
potential misuse of ACT when deployed beyond the
health system [6,7], which could lead to wastage of
resources and the development of resistance to ACT. How-
ever, our findings indicate that there was appropriate pre-
scription in terms of dose by CMDs and correct use by
caregivers. In all study sites, 97% or more of the CMDs
prescribed the correct dose of ACTs, and almost all of
them explained the treatment schedule to the caregiver.
Drug storage conditions were satisfactory in all sites.
These studies were designed for the CMDs to provide
treatment on the basis of a clinical diagnosis. The possibil-
ity of moving away from a symptom based treatment to
more complex therapeutic protocols based on parasito-
logical confirmation is currently being investigated. To
bring parasitological diagnosis to the community level
will require reliable diagnostic tools, and evidence of fea-
sibility and acceptability by the community.
Adherence to the full treatment course has been high-
lighted as a matter of concern [14-16]. AL has to be taken
twice a day for three days (one or two tablets depending
on the age group), AS/AQ once daily for three days but
two different tablets (or half tablets) each time. Both of
these regimens are different from those for older antima-
larials like chloroquine or sulphadoxine-pyrimethamine
(SP). Nonetheless, reported adherence by caregivers to the
correct treatment schedule in terms of dose and duration
was high for both treatment regimes in all sites, ranging
from 79% in Uganda to 97% in Ejisu, Ghana (85% on
average across the sites). These findings are reassuring
with regard to the potential for development of resistance,
as exposure to sub-therapeutic drug levels is known to be
a major factor i
n the selection of resistant parasites [17].
Furthermore, the majority of caregivers obtaining ACT
from a CMD reported that they treated their children
promptly (ranging from 86% to 97%, 90% on average
across the sites, Table 5). Data from CMDs' registers
(Table 2) support this finding, albeit with slightly lower
proportions of children recorded to be treated on the day
of onset or the next day in three sites. In Uganda, CMDs
reported treating only half of the episodes within 24
hours, a proportion which is still substantially higher than
previously reported by Nsungwa-Sabiiti [16]. The design
Table 6: Safety and perceived effectiveness of treatment of ACTs obtained from CMDs
Ejisu – Juaben 
District, Ghana
Ho District, 
Ghana
Badeku and Ojoku/Ajia 
Districts, Nigeria
Bugiri and Iganga 
Districts, Uganda
Totals
CMD registers
Number of episodes treated with ACTs from a 
CMD (CMD registers)
4522 3958 1044 11039 20563
Number (%) of children reporting an adverse event 
to a CMD
63 (1%) 10 (<1%) NA NA
Number (%) children reported recovered NA NA NA NA
Survey data
Number of episodes treated with ACTs from a 
CMD (surveys)
289 93 288 619 1289
Number (%) of children reporting an adverse event 
at survey
24 (8%) 7 (8%) 10 (4%) 34 (6%) 75 (6%)
Number (%) children reported recovered NA NA 284 (99%) NA 284 (99%)
Number of caregivers (%) who perceived treatment 
to be effective
286 (99%) 93 (100%) 280 (97%) NA 659 (98%)
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of this study does not provide robust data on pharma-
covigilance. However, both CMDs and caregivers report a
very low incidence of adverse drug effects, none of which
were reported to be serious.
Access to prompt and effective treatment is a cornerstone
of the current malaria control strategy [18]. Several strate-
gies have been developed to address the issue of access to
antimalarials in Africa, including home management of
malaria [1], improving the services of private medicine
sellers [19], a set of integrated interventions including
social marketing approaches [20] and improving the qual-
ity of health service performance [21]. Our study provides
evidence that once the option of treating children with
effective antimalarials close to home is made available to
caregivers, a majority of them (ranging from 52% in
Nigeria to 75% in Ho, Ghana) make use of it, in most
cases in an appropriate and timely manner. This option
should be regarded as a complementary to, rather than
competing with, health facility delivery of care. As high-
lighted by Unger et al [21], interventions aiming at
improving use rates of general health services have also a
high potential of increasing malaria cure rates.
Overall effectiveness of drugs distributed at the commu-
nity level is known to be influenced by several factors
[16,22,23], not all of them addressed in this study. How-
ever, the high level of correct prescription by CMDs, the
promptness of treatment seeking and adherence to the
treatment schedule by caregivers, and the coverage (59%
on average across the sites) achieved in this study show
that some key factors determining the effectiveness of
antimalarial treatment can be successfully addressed.
Thus, this approach has great potential to contribute to
reaching the Abuja target that "at least 60% of those suffer-
ing from malaria have prompt access to, and are able to cor-
rectly use, affordable and appropriate treatment within 24
hours of the onset of symptoms" [2].
Previous studies have shown that use of the correct dose
of chloroquine in uncomplicated malaria correlates with
improvements in clinical condition [24], and that HMM
with chloroquine has been effective in reducing both mor-
tality[25] and severe malaria morbidity [26]. Studies in
Uganda and Tanzania [27,28] have recently shown that
the high parasitological cure rate of AL is not affected by
unsupervised administration under routine clinical prac-
tice. A sub-study evaluating parasitological efficacy of the
ACTs used in this study is being undertaken and will be
reported on separately.
This study shows that ACT use can be successfully inte-
grated in the HMM strategy.
While further studies are necessary to develop mecha-
nisms for ensuring long-term performance of CMDs and
to evaluate the effectiveness and safety of ACTs used
within the context of HMM programmes, the findings of
this study provide evidence to support scaling-up imple-
mentation of HMM with ACTs.
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